Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid for bone density preservation in premenopausal women with hormone receptor-negative breast cancer receiving adjuvant chemotherapy
2004-002831-14Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Zometa with Placebo (2 arms). Primary endpoint: Change in lumbar spine bone mineral density. Started Aug 2005; status: completed.
02
Drugs
zoledronic acid
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2004-002831-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002831-14.